antimalari
drug
use
treatment
prevent
malaria
classifi
heterogen
group
usual
divid
base
chemic
structur
sourc
drug
deriv
tradit
medicin
plant
identif
activ
principl
chemic
modif
introduc
increas
activ
amelior
select
index
present
differ
mode
variou
mechan
action
often
still
elucid
malaria
parasit
furthermor
due
complex
molecul
addit
side
activ
report
reason
antimalari
drug
studi
propos
sometim
use
treatment
patholog
cancer
autoimmun
diseas
nonmalaria
infecti
diseas
moreov
geograph
overlap
malaria
viralrel
diseas
led
consider
possibl
use
antimalari
drug
new
antivir
drug
final
lack
new
effect
antivir
drug
vaccin
mani
viral
infect
strengthen
interest
potenti
antivir
activ
antimalari
drug
present
review
author
present
use
efficaci
human
virus
princip
antimalari
drug
divid
four
main
group
artemisinin
deriv
arylaminoalcohol
aminoquinolin
antimicrobi
drug
chemic
structur
cite
compound
summar
figur
work
newli
synthes
deriv
licens
taken
consider
possibl
origin
manuscript
cite
howev
previou
work
scientist
acknowledg
also
cite
review
articl
aim
provid
comprehens
list
publish
paper
propos
field
art
activ
principl
extract
artemisia
annua
poorli
solubl
water
oil
thu
develop
semisynthet
deriv
necessari
appropri
formul
poor
physicochem
properti
may
account
scarc
literatur
use
art
antivir
art
dihydroartemisinin
dha
artesun
compar
antihcmv
effect
fibroblast
cell
model
measur
viral
dna
synthesi
cellular
lysat
art
show
lowest
activ
even
fraction
dose
daili
repeat
administr
use
counteract
problem
instabl
compound
cultur
medium
compar
compound
tradit
chines
medicin
art
also
activ
low
toxic
inhibit
hepat
b
viru
hbv
measur
hepat
b
surfac
antigen
hbsag
dna
releas
cultur
medium
moreov
synerg
antivir
lamivudin
demonstr
art
downregul
oncogen
human
papillomaviru
hpv
protein
vitro
model
cervic
carcinoma
result
partial
confirm
report
disbrow
colleagu
observ
antiprolif
effect
dha
canin
oral
papillomaviru
art
also
inhibit
hepat
c
viru
hcv
replicon
replic
effect
synergist
hemin
iron
donor
final
art
show
inhibit
human
immunodefici
viru
hiv
replic
effect
reproduc
differ
cell
model
activ
replic
hcmv
demonstr
differ
vitro
cell
model
fibroblast
tumor
cell
compar
art
deriv
highest
activ
activ
compar
even
higher
classic
antivir
drug
ganciclovir
antivir
effect
confirm
differ
multidrugresist
strain
differ
method
plaqu
assay
luminescentfluoresc
method
base
use
transgen
viral
strain
case
effect
synergist
antivir
drug
maribavir
lamivudin
ganciclovir
foscarnet
cidofovir
letermovir
howev
vitro
data
regard
synerg
alway
confirm
experiment
condit
case
report
synerg
maribavir
confirm
ex
vivo
placenta
model
moreov
data
obtain
anim
model
avail
rat
cmvrat
model
demonstr
antivir
activ
measur
dissemin
viru
salivari
gland
number
viral
genom
copi
viru
titer
salivari
gland
activ
exert
coadminist
iron
formul
associ
valacyclovir
test
murin
model
herp
simplex
viru
enceph
hse
evalu
antivir
also
immunomodul
activ
would
benefici
diseas
model
surviv
rate
mice
treat
drug
higher
mice
treat
valacyclovir
alon
signific
differ
observ
brain
viral
load
level
cytokin
interleukin
il
interferon
ifn
reduc
mice
treat
valacyclovir
combin
art
versu
mice
treat
valacyclovir
alon
clinic
data
support
use
hcmv
contrast
case
report
rapid
decreas
viral
load
observ
stem
cell
transplant
recipi
infect
newli
identifi
foscarnetresist
ganciclovirresist
hcmv
strain
treat
regard
clinic
trial
regist
use
stem
cell
transplant
recipi
although
recruit
patient
israel
complet
result
avail
yet
tabl
hand
renal
transplant
recipi
patient
document
valganciclovir
resist
mutat
hcmv
treat
posit
effect
third
case
report
patient
multidrugresist
hcmv
infect
difficult
interpret
due
complic
seri
treatment
two
hematopoiet
stem
cell
transplant
consequ
acut
graftversushost
diseas
episod
patient
given
associ
maribavir
withdrawn
two
week
initi
orthostat
hypotens
wolf
colleagu
describ
six
case
stem
cell
transplant
recipi
receiv
preemptiv
treatment
hcmv
infect
two
show
decreas
viral
load
anoth
studi
five
transplant
patient
infect
hcmv
strain
resist
differ
antivir
drug
treat
mani
unsuccess
cycl
antivir
treatment
three
five
favor
outcom
present
art
deriv
recommend
antimalari
treatment
combin
anoth
molecul
differ
mechan
action
longer
halflif
art
combin
therapi
act
avoid
onset
resist
prevent
recrudesc
one
combin
plu
amodiaquin
aq
test
hcmv
clinic
studi
conduct
ugandan
children
treat
acut
malaria
either
act
plu
aq
measur
differ
observ
either
hcmv
detect
frequenc
load
blood
children
two
group
effect
low
micromolar
rang
epstein
barr
viru
ebv
epitheli
cell
lymphocyt
antivir
activ
human
herp
demonstr
vitro
also
child
affect
myocard
treatment
associ
decreas
level
dna
myocardium
howev
data
effect
contrast
literatur
affect
human
bk
polyomaviru
bkpyv
jc
polyomaviru
jcpyv
replic
vitro
virus
latent
asymptomat
infect
human
host
abl
reactiv
immunosuppress
host
hivposit
patient
transplant
recipi
jcpyv
caus
rare
fatal
diseas
known
progress
multifoc
leukoencephalopathi
pml
bkpyv
associ
nephropathi
mention
art
activ
hbv
less
toxic
compound
tradit
chines
medicin
reduct
hcv
replicon
caus
dose
timedepend
vitro
increas
given
associ
ifn
interestingli
usa
openlabel
studi
current
investig
novel
nonsurg
approach
treatment
hpvassoci
anal
intraepitheli
highgrad
neoplasia
use
suppositori
outcom
verifi
regress
lesion
clearanc
hpv
similarli
phase
ii
doubleblind
placebocontrol
random
studi
vagin
insert
design
treatment
women
cervic
highgrad
intraepitheli
neoplasia
recruit
yet
start
tabl
final
combin
asaq
also
use
patient
infect
ebola
viru
ebov
reduc
mortal
risk
act
use
artemetherlumefantrin
howev
moder
seriou
risk
bia
small
sampl
size
preclud
conclus
ebov
diseas
epidem
west
africa
two
mass
drug
administr
asaq
implement
decreas
burden
malaria
garbern
colleagu
perform
retrospect
studi
assess
potenti
effect
treatment
mortal
patient
ebov
although
risk
mortal
treat
patient
compar
ebov
infect
patient
expos
asaq
decreas
effect
signific
prospect
trial
need
activ
differ
art
deriv
evalu
hcmv
fibroblast
model
use
luminesc
assay
base
transgen
viral
strain
compar
andor
art
artemeth
activ
howev
activ
seen
micromolar
rang
concentr
synthesi
dimer
allow
activ
effect
nanomolar
concentr
dha
activ
metabolit
art
deriv
antimalari
drug
dha
art
test
bovin
viral
diarrhea
viru
bvdv
surrog
vitro
model
hcv
show
moder
activ
micromolar
concentr
rang
artemeth
often
use
combin
lumefantrin
one
commerci
version
combin
use
prospect
observ
studi
mali
children
year
coinfect
hcmv
malaria
viral
load
urin
decreas
high
viru
shedder
artemetherlumefantrin
combin
also
use
patient
infect
ebov
show
reduc
efficaci
reduc
risk
death
compar
asaq
alreadi
describ
artesun
paragraph
quinin
alkaloid
extract
chinchona
quinaquina
tree
bark
discov
centuri
use
treat
malaria
sinc
earli
current
still
play
pivot
role
especi
treatment
chloroquin
cq
resist
plasmodium
falciparum
due
benefit
deriv
antimalari
drug
patholog
possibl
antivir
effect
quinin
investig
first
manuscript
regard
effect
quinin
influenza
viru
infect
mice
publish
subsequ
vitro
evalu
quinin
sulfat
conduct
virus
herp
simplex
influenza
viru
iav
quinin
sulfat
micromolar
toxic
dose
reduc
number
plaqu
form
vitro
vero
hacat
cell
model
although
viricid
activ
observ
quinin
sulfat
vitro
activ
also
test
iav
mean
viral
plaqu
inhibit
assay
evalu
prophylact
activ
show
differ
effect
within
micromolar
rang
depend
viral
strain
recent
quinin
sulfat
test
vitro
emerg
dengu
viru
denv
strain
differ
cell
line
show
reduct
virion
product
compar
untreat
control
concentrationdepend
reduct
denv
rna
viral
protein
inhibit
replic
confirm
four
differ
serotyp
denv
mefloquin
mq
synthet
analog
quinin
long
histori
use
good
safeti
human
wide
test
antivir
one
first
report
refer
jcpyv
brickelmai
et
al
chose
mq
high
bloodbrain
barrier
penetr
capabl
sinc
accumul
brain
tissu
sixfold
higher
concentr
mq
activ
differ
strain
jcpyv
three
differ
cell
model
within
low
micromolar
rang
absenc
suitabl
anim
model
first
paper
repres
start
point
seri
trial
human
popul
obtain
contrast
result
summar
tabl
seventeen
case
report
describ
use
mq
differ
dose
although
case
progress
diseas
followup
difficult
draw
conclus
due
challeng
treatment
protocol
compromis
health
patient
mani
case
mq
combin
mirtazapin
antidepress
act
serotonin
receptor
abl
inhibit
jcpyv
entri
glial
cell
prevent
diffus
infect
oligodendrocyt
outcom
treatment
controversi
lead
resolut
infect
claim
effect
mq
mirtazapin
treatment
resolut
infect
probabl
due
factor
death
patient
alway
directli
relat
unsuccess
therapi
one
case
suspens
therapi
necessari
due
side
effect
case
third
partner
drug
ad
mq
mirtazapin
outcom
variabl
contribut
singl
drug
difficult
determin
mq
also
combin
risperidon
risperidon
cytarabin
final
outcom
oppos
either
death
recoveri
patient
one
case
mq
administ
antivir
cidofovir
result
final
remiss
patholog
like
due
synergi
factor
differ
case
report
describ
use
mq
hivposit
pml
patient
sometim
repress
jcpyv
replic
rare
death
patient
combin
treatment
mq
mirtazapin
administ
hivposit
patient
lead
failur
prematur
death
alway
due
pml
one
random
studi
conduct
hivposit
hivneg
patient
compar
efficaci
standard
care
normal
use
treat
pml
standard
care
supplement
mq
studi
end
prematur
lack
signific
differ
two
group
studi
antivir
effect
mq
iav
perform
maroi
et
al
mq
show
differ
grade
efficaci
depend
viral
strain
rang
partial
inhibit
replic
total
ineffect
recent
effect
mq
emerg
virus
studi
mq
test
first
time
zika
viru
zikv
show
differ
reduct
infect
rate
depend
cell
model
use
differ
cytotox
thu
make
difficult
draw
conclus
balasubramanian
et
al
confirm
vitro
effect
mq
zikv
infect
evalu
denv
perform
sever
vitro
assay
sun
et
al
perform
vitro
screen
fixeddos
drug
combin
three
molecul
choos
abl
block
ebovlik
particl
entri
hela
cell
one
three
best
combin
compos
mq
toremifen
antagonist
estrogen
receptor
antifung
posaconazol
whose
activ
confirm
doserespons
experi
vero
cell
infect
ebov
although
benefit
could
seen
use
mq
antivir
drug
neurotox
taken
account
use
malaria
prophylaxi
known
caus
seriou
neuropsychiatr
advers
reaction
date
intern
mq
label
warn
patient
discontinu
onset
prodrom
psychiatr
neurolog
symptom
howev
date
best
knowledg
systemat
studi
concern
neurotox
manifest
mq
use
ad
antivir
drug
antimalari
prophylaxi
could
specul
condit
benefit
risk
ratio
would
look
favor
mq
use
malaria
chemoprophylaxi
good
result
obtain
use
quinin
sulfat
mq
antivir
state
halofantrin
lumefantrin
fail
inhibit
viral
replic
base
studi
conduct
date
mazzon
colleagu
perform
vitro
screen
compound
abl
describ
inhibit
activ
halofantrin
semliki
forest
viru
sfv
due
low
select
index
drug
investig
conduct
lumefantrin
test
commerci
combin
artemeth
known
previous
describ
paragraph
art
deriv
chloroquin
cq
aminoquinolin
known
sinc
synthes
use
antimalari
drug
properti
mechan
action
encourag
use
treatment
differ
diseas
current
cq
hydroxyanalog
hydroxychloroquin
hydroxycq
use
antimalari
drug
wide
area
resist
malaria
parasit
emerg
commonli
use
connect
tissu
disord
rheumatoid
arthriti
due
low
toxic
cost
high
toler
immunomodulatori
properti
cq
hydroxycq
also
propos
use
viral
infect
even
specif
mechan
individu
diseas
clear
well
assess
antivir
activ
aminoquinolin
take
advantag
strong
antiinflammatori
activ
major
propos
mechan
action
cq
analog
suggest
influenc
antivir
activ
among
other
inhibit
cytokin
product
releas
cell
tumor
necrosi
factor
reduc
level
chemokin
inhibit
microrna
express
decreas
cytokin
decreas
dna
rna
protein
synthesi
thymocyt
review
vitro
antivir
effect
cq
first
report
approxim
year
ago
sinc
time
use
antivir
drug
extens
discuss
particular
cqhydroxycq
use
treatment
emerg
chikungunya
viru
chikv
infect
recent
caus
numer
outbreak
world
khan
et
al
show
treatment
infect
vero
cell
differ
micromolar
concentr
cq
reduc
viru
yield
viral
rna
copi
number
de
lamballeri
colleagu
confirm
inhibit
chikv
replic
cell
use
cq
efficaci
cq
invers
relat
concentr
viral
inoculum
use
unfavor
observ
consid
high
viremia
measur
acut
stage
chikv
infect
viru
copiesml
serum
sourisseau
colleagu
treat
hela
cell
cq
obtain
potent
inhibit
chikv
replic
rel
cytopath
effect
doubleblind
placebocontrol
trial
design
evalu
efficaci
safeti
cq
treatment
chikv
infect
french
reunion
island
indian
ocean
signific
differ
observ
cq
placebo
group
either
mean
durat
febril
arthralgia
rate
viremia
decreas
howev
number
patient
includ
studi
small
draw
definit
conclus
regard
efficaci
cq
treatment
tabl
aminoquinolin
propos
treatment
viral
infect
zikv
demonstr
cq
aq
exert
antizikv
activ
vero
cell
low
micromolar
result
agreement
decreas
number
zikvinfect
cell
cq
treatment
addit
cq
protect
cell
zikv
infect
measur
cell
viabil
noncytotox
concentr
activ
cq
also
indirectli
demonstr
denv
infect
result
obtain
kleber
colleagu
show
cq
suppress
product
hypothes
cq
might
use
treat
patient
suspect
dengu
diseas
avoid
sever
form
dengu
hemorrhag
fever
andor
shock
clinic
trial
also
establish
verifi
effect
cq
versu
placebo
denvinfect
patient
brazil
cq
promot
reduct
intens
pain
improv
wellb
patient
denv
infect
alter
durat
diseas
intens
day
fever
tabl
studi
effect
cq
ebov
group
led
dowal
conduct
vitro
investig
use
human
cell
line
vivo
studi
wellcharacter
guinea
pig
model
abl
demonstr
cq
reduc
ebov
replic
cell
contrast
administr
cq
guinea
pig
protect
infect
anim
ebola
diseas
madrid
colleagu
suggest
cq
could
interfer
late
stage
ebov
replic
assembl
despit
posit
vitro
result
clinic
trial
sometim
conflict
reason
later
literatur
review
clarifi
efficaci
cq
treatment
filoviru
infect
conclud
efficaci
cq
virus
belong
famili
depend
cq
plasma
concentr
must
sustain
patient
clearanc
viremia
cq
shown
inhibit
replic
spread
coronaviru
cov
vitro
prevent
infect
cov
newborn
mice
sinc
suppress
effect
cq
also
present
cell
treat
infect
prophylact
advantag
cq
use
suggest
cq
analog
effect
hcv
particular
treatment
cell
cq
reduc
hcv
entri
replic
infect
dosedepend
manner
furthermor
cq
combin
prevent
replic
hcv
enhanc
antivir
effect
regard
two
phase
iii
clinic
trial
initi
verifi
efficaci
combin
treatment
hydroxycq
ribavirin
result
post
due
limit
recruit
cq
shown
inhibit
vitro
replic
iav
strain
phase
ii
clinic
trial
aim
verifi
effect
cq
compar
placebo
iav
start
singapor
patient
recruit
howev
cq
shown
prevent
infect
iav
tabl
cq
inhibitori
effect
entri
replic
enteroviru
ev
cellbas
system
yong
colleagu
studi
efficaci
cq
sever
ev
serotyp
evalu
therapeut
capac
vitro
rd
cell
vivo
murin
model
demonstr
potenti
cq
antivir
treatment
hand
foot
mouth
diseas
caus
ev
infect
posit
result
obtain
murin
model
infect
indic
fact
cq
may
mitig
diseas
sever
mammal
amodiaquin
aq
origin
develop
wide
use
treatment
malaria
howev
subsequ
studi
reveal
activ
wide
rang
human
pathogen
includ
sever
virus
studi
publish
investig
whether
quinolon
deriv
could
inhibit
replic
denv
timecours
analysi
suggest
aq
stabl
reproduc
inhibit
denv
infect
data
also
show
viral
entri
intern
partial
inhibit
drug
major
effect
occur
later
stage
viral
life
cycl
known
aq
inhibit
ebov
replic
vivo
recent
studi
demonstr
aq
activ
sever
fever
thrombocytopenia
syndrom
sft
caus
sft
viru
sftsv
primaquin
test
antivir
primari
chicken
embryo
cell
cec
infect
newcastl
diseas
viru
demonstr
primaquin
effect
accumul
viral
hemagglutinin
cell
surfac
addit
primaquin
inhibit
protein
synthesi
virusinfect
cell
atovaquon
naphthoquinon
antimalari
drug
often
use
pregnant
women
ubiquinon
coenzym
q
analog
inhibit
mitochondri
cytochrom
complex
iii
complex
also
abl
deplet
intracellular
nucleotid
pool
inhibit
dihydroorot
dehydrogenas
enzym
de
novo
pyrimidin
synthesi
one
publish
work
report
vitro
antivir
action
atovaquon
chikv
low
micromolar
dose
inhibit
number
infect
cell
evalu
highcont
fluoresc
microscopi
result
confirm
reduct
chikv
virion
differ
cell
plaqu
assay
paper
kottkamp
colleagu
evalu
abil
atovaquon
reduc
infect
brazilian
ugandan
strain
zikv
immunostain
envelop
treatment
infect
subsequ
plaqu
assay
differ
cell
data
confirm
ex
vivo
human
placenta
tissu
model
dosedepend
reduct
infect
virion
product
ugandan
strain
doxycyclin
dox
semisynthet
tetracyclin
antibiot
prevent
bacteri
protein
synthesi
act
ribosom
subunit
dox
wide
use
alon
combin
quinin
chemoprophylaxi
cqresist
p
falciparum
case
malaria
shown
exert
inhibitori
effect
differ
microbi
infect
dox
significantli
inhibit
prolifer
panel
hpvposit
cervic
cancer
cell
line
also
induc
apoptosi
cervic
cancer
cell
time
dosedepend
manner
concern
emerg
infect
recent
work
research
tri
identifi
candid
antibiot
block
function
denv
viral
envelop
protein
prevent
viral
entri
use
innov
visual
screen
approach
coupl
comput
studi
biolog
assay
ten
nontox
candid
suggest
dox
significantli
inhibit
plaqu
format
demonstr
inhibitori
effect
denv
propag
result
confirm
rothan
colleagu
evalu
replic
rate
denv
vitro
model
infect
cell
report
dox
inhibit
denv
replic
vitro
reduc
viral
proteas
activ
entri
host
cell
research
group
determin
inhibitori
effect
dox
chikv
well
possibl
effect
viru
life
cycl
vero
cell
viru
drug
administ
concurr
cell
comput
studi
indic
dox
might
noncompetit
inhibitor
chikv
proteas
hypothesi
confirm
vitro
experi
demonstr
effect
dox
direct
toward
viral
entri
toward
viral
replic
furthermor
inhibitori
effect
dox
replic
vesicular
stomat
viru
vsv
differ
stabli
infect
cell
line
report
result
show
signific
inhibit
replic
vsv
dosedepend
celltyp
depend
manner
suggest
dox
exert
antivir
activ
earlymid
stage
vsv
infect
result
indic
differ
mode
action
dox
vsv
denv
chikv
suggest
antivir
activ
dox
could
depend
viru
speci
final
vivo
studi
publish
iav
treatment
dox
attenu
acut
lung
injuri
mice
infect
virul
iav
strain
effect
viru
titer
suggest
antibiot
treatment
abl
allevi
sever
influenza
pneumonia
symptom
therefor
possibl
conclud
despit
role
dox
potenti
antivir
agent
vitro
mechan
viral
replic
inhibit
target
viru
speci
yet
clarifi
clinic
trial
confirm
vitro
observ
need
sulfonamid
constitut
import
class
drug
contain
mani
type
pharmacolog
agent
broadspectrum
bacteriostat
activ
sulfonamid
interrupt
synthesi
folic
acid
interf
dihydroptero
synthas
dihydrofol
reductas
enzym
bacteria
protozoa
inhibit
bacteri
growth
sulfadoxinepyrimethamin
combin
use
set
treatment
uncompl
malaria
pregnant
women
drug
current
recommend
intermitt
prevent
therapi
pregnanc
studi
investig
effect
combin
hiv
replic
experi
conduct
vitro
use
peripher
blood
mononuclear
cell
cell
cell
latent
infect
cell
line
name
result
show
sulfadoxinepyrimethamin
combin
combin
antiretrovir
therapi
significantli
enhanc
hiv
replic
cell
inhibit
hiv
replic
peripher
blood
mononuclear
cell
moreov
recent
studi
demonstr
sulfonamid
act
latent
herpesvirus
ebv
kaposi
sarcoma
herpesviru
kshv
furthermor
work
conduct
angiu
colleagu
report
sulfonamid
antibiot
suppress
kshv
latent
state
perman
infect
lymphoma
cell
result
suggest
sulfonamid
might
play
potenti
role
clear
kshvinfect
lymphoma
cell
sinc
convent
antiherp
drug
abl
slightli
suppress
viral
replic
lytic
phase
clear
latent
state
find
potenti
new
small
molecul
sulfonamid
drug
could
initi
promis
program
studi
oncogen
degen
diseas
herpesviru
latenc
suspect
involv
antimalari
drug
wide
test
larg
number
virus
especi
vitro
variabl
outcom
tabl
among
art
deriv
show
strong
activ
virus
hcmv
art
hbv
hcv
hpv
hpyv
wherea
data
regard
activ
hiv
uncertain
among
arylaminoalcohol
use
mq
treatment
jcpyv
infect
extens
although
contradictori
outcom
among
aminoquinolin
cq
hydroxycq
show
promis
result
reduc
replic
emerg
virus
denv
zikv
emerg
infect
also
target
antibacteri
drug
dox
howev
success
use
antimalari
drug
vitro
alway
lead
satisfactori
outcom
clinic
applic
tabl
nevertheless
drug
alreadi
use
sever
clinic
trial
summar
tabl
regard
use
antimalari
drug
hiv
infect
fail
other
final
result
avail
although
outcom
seem
discourag
least
four
clinic
trial
deserv
attent
one
use
hcmv
particular
regard
drugresist
strain
one
target
chikv
cq
two
innov
ongo
trial
use
hpv
treatment
anal
cervic
intraepitheli
highgrad
neoplasia
base
observ
state
use
antimalari
drug
might
use
especi
case
antivir
resist
light
emerg
mani
virus
effect
drug
avail
